Hillman N, Herranz L, Alvarez C, Martínez Olmos M A, Márco A, Gómez-Pan A
Department of Endocrinology, Hospital La Paz, Autónoma University of Madrid, Spain.
Exp Clin Endocrinol Diabetes. 1998;106(3):226-30. doi: 10.1055/s-0029-1211980.
We present the case of a 52-year old patient diagnosed with carcinoid tumour of the rectum with liver metastases in which treatment with somatostatin analogues (octreotide) proved very effective in the disappearance of the symptomatology and dramatic efficacy in the regression of the tumour. Imaging by octreoscan was always negative. The role of octreotide in the treatment of carcinoid tumour and the usefulness of In-111-pentetreotide (octreoscan) in the localization and prediction of the response to treatment with octreotide is discussed. We conclude that the negative result of the scintigraphic image with octreoscan does not necessarily suppose the inefficacy of octreotide treatment. We believe that this may constitute an important issue since some patients may be denied octreotide treatment in the absence of a positive octreoscan result.
我们报告一例52岁诊断为直肠类癌伴肝转移的患者,使用生长抑素类似物(奥曲肽)治疗后症状消失且肿瘤消退效果显著。奥曲肽扫描成像始终为阴性。本文讨论了奥曲肽在类癌治疗中的作用以及铟-111-喷替肽(奥曲肽扫描)在定位和预测奥曲肽治疗反应方面的实用性。我们得出结论,奥曲肽扫描的闪烁图像阴性不一定意味着奥曲肽治疗无效。我们认为这可能是一个重要问题,因为在奥曲肽扫描结果为阴性时,一些患者可能会被拒绝使用奥曲肽治疗。